allodynia from tirzepatide Allodynia: Unusual Complication of GLP-1 Medications Frontiers | Analysis of tirzepatide

Similarly, tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrated impressive results in the SYNERGY-NASH trial, with a high percentage (74%) of participants achieving an absence of NASH and no worsening of fibrosis

Published: 2025-08-28 Pages: 76 The global market for Tirzepatide Injection was estimated to be worth US$ 16505 million in 2024 and is forecast to a readjusted size of US$ 51045 million by 2031 with a CAGR of 15.5% during the forecast period 2025-2031

The SURPASS-CVOT trial for Mounjaro cardiovascular outcomes is ongoing, with data expected by 2029

Moreover, the combined effect of GLP-1RAs with other molecules may vary depending on sex